Serveur d'exploration sur les pandémies grippales

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

In vivo mallard experiments indicate that zanamivir has less potential for environmental influenza A virus resistance development than oseltamivir.

Identifieur interne : 000356 ( PubMed/Curation ); précédent : 000355; suivant : 000357

In vivo mallard experiments indicate that zanamivir has less potential for environmental influenza A virus resistance development than oseltamivir.

Auteurs : Marie Nykvist [Suède] ; Anna Gillman [Suède] ; Hanna Söderström Lindström [Suède] ; Chaojun Tang [Suède] ; Ganna Fedorova [République tchèque] ; Ke Lundkvist [Suède] ; Neus Latorre-Margalef [Suède] ; Michelle Wille [Suède] ; Josef D. J Rhult [Suède]

Source :

RBID : pubmed:29139346

Abstract

Neuraminidase inhibitors are a cornerstone of influenza pandemic preparedness before vaccines can be mass-produced and thus a neuraminidase inhibitor-resistant pandemic is a serious threat to public health. Earlier work has demonstrated the potential for development and persistence of oseltamivir resistance in influenza A viruses exposed to environmentally relevant water concentrations of the drug when infecting mallards, the natural influenza reservoir that serves as the genetic base for human pandemics. As zanamivir is the major second-line neuraminidase inhibitor treatment, this study aimed to assess the potential for development and persistence of zanamivir resistance in an in vivo mallard model; especially important as zanamivir will probably be increasingly used. Our results indicate less potential for development and persistence of resistance due to zanamivir than oseltamivir in an environmental setting. This conclusion is based on: (1) the lower increase in zanamivir IC50 conferred by the mutations caused by zanamivir exposure (2-17-fold); (2) the higher zanamivir water concentration needed to induce resistance (at least 10 µg l-1); (3) the lack of zanamivir resistance persistence without drug pressure; and (4) the multiple resistance-related substitutions seen during zanamivir exposure (V116A, A138V, R152K, T157I and D199G) suggesting lack of one straight-forward evolutionary path to resistance. Our study also adds further evidence regarding the stability of the oseltamivir-induced substitution H275Y without drug pressure, and demonstrates the ability of a H275Y-carrying virus to acquire secondary mutations, further boosting oseltamivir resistance when exposed to zanamivir. Similar studies using influenza A viruses of the N2-phylogenetic group of neuraminidases are recommended.

DOI: 10.1099/jgv.0.000977
PubMed: 29139346

Links toward previous steps (curation, corpus...)


Links to Exploration step

pubmed:29139346

Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">
<i>In vivo</i>
mallard experiments indicate that zanamivir has less potential for environmental influenza A virus resistance development than oseltamivir.</title>
<author>
<name sortKey="Nykvist, Marie" sort="Nykvist, Marie" uniqKey="Nykvist M" first="Marie" last="Nykvist">Marie Nykvist</name>
<affiliation wicri:level="1">
<nlm:affiliation>Zoonosis Science Center, Department of Medical Biochemistry and Microbiology, Uppsala University, Uppsala, Sweden.</nlm:affiliation>
<country xml:lang="fr">Suède</country>
<wicri:regionArea>Zoonosis Science Center, Department of Medical Biochemistry and Microbiology, Uppsala University, Uppsala</wicri:regionArea>
</affiliation>
</author>
<author>
<name sortKey="Gillman, Anna" sort="Gillman, Anna" uniqKey="Gillman A" first="Anna" last="Gillman">Anna Gillman</name>
<affiliation wicri:level="1">
<nlm:affiliation>Section for Infectious Diseases, Department of Medical Sciences, Uppsala University, Uppsala, Sweden.</nlm:affiliation>
<country xml:lang="fr">Suède</country>
<wicri:regionArea>Section for Infectious Diseases, Department of Medical Sciences, Uppsala University, Uppsala</wicri:regionArea>
</affiliation>
</author>
<author>
<name sortKey="Soderstrom Lindstrom, Hanna" sort="Soderstrom Lindstrom, Hanna" uniqKey="Soderstrom Lindstrom H" first="Hanna" last="Söderström Lindström">Hanna Söderström Lindström</name>
<affiliation wicri:level="1">
<nlm:affiliation>Department of Chemistry, Umeå University, Umeå, Sweden.</nlm:affiliation>
<country xml:lang="fr">Suède</country>
<wicri:regionArea>Department of Chemistry, Umeå University, Umeå</wicri:regionArea>
</affiliation>
</author>
<author>
<name sortKey="Tang, Chaojun" sort="Tang, Chaojun" uniqKey="Tang C" first="Chaojun" last="Tang">Chaojun Tang</name>
<affiliation wicri:level="1">
<nlm:affiliation>Department of Chemistry, Umeå University, Umeå, Sweden.</nlm:affiliation>
<country xml:lang="fr">Suède</country>
<wicri:regionArea>Department of Chemistry, Umeå University, Umeå</wicri:regionArea>
</affiliation>
</author>
<author>
<name sortKey="Fedorova, Ganna" sort="Fedorova, Ganna" uniqKey="Fedorova G" first="Ganna" last="Fedorova">Ganna Fedorova</name>
<affiliation wicri:level="1">
<nlm:affiliation>University of South Bohemia in Ceske Budejovice, Faculty of Fisheries and Protection of Waters, South Bohemian Research Center of Aquaculture and Biodiversity of Hydrocenoses, Vodnany, Czech Republic.</nlm:affiliation>
<country xml:lang="fr">République tchèque</country>
<wicri:regionArea>University of South Bohemia in Ceske Budejovice, Faculty of Fisheries and Protection of Waters, South Bohemian Research Center of Aquaculture and Biodiversity of Hydrocenoses, Vodnany</wicri:regionArea>
</affiliation>
</author>
<author>
<name sortKey="Lundkvist, Ke" sort="Lundkvist, Ke" uniqKey="Lundkvist " first=" Ke" last="Lundkvist"> Ke Lundkvist</name>
<affiliation wicri:level="1">
<nlm:affiliation>Zoonosis Science Center, Department of Medical Biochemistry and Microbiology, Uppsala University, Uppsala, Sweden.</nlm:affiliation>
<country xml:lang="fr">Suède</country>
<wicri:regionArea>Zoonosis Science Center, Department of Medical Biochemistry and Microbiology, Uppsala University, Uppsala</wicri:regionArea>
</affiliation>
</author>
<author>
<name sortKey="Latorre Margalef, Neus" sort="Latorre Margalef, Neus" uniqKey="Latorre Margalef N" first="Neus" last="Latorre-Margalef">Neus Latorre-Margalef</name>
<affiliation wicri:level="1">
<nlm:affiliation>Centre for Ecology and Evolution in Microbial Model Systems (EEMiS), Faculty of Health and Life Sciences, Linnaeus University, Kalmar, Sweden.</nlm:affiliation>
<country xml:lang="fr">Suède</country>
<wicri:regionArea>Centre for Ecology and Evolution in Microbial Model Systems (EEMiS), Faculty of Health and Life Sciences, Linnaeus University, Kalmar</wicri:regionArea>
</affiliation>
</author>
<author>
<name sortKey="Wille, Michelle" sort="Wille, Michelle" uniqKey="Wille M" first="Michelle" last="Wille">Michelle Wille</name>
<affiliation wicri:level="1">
<nlm:affiliation>Zoonosis Science Center, Department of Medical Biochemistry and Microbiology, Uppsala University, Uppsala, Sweden.</nlm:affiliation>
<country xml:lang="fr">Suède</country>
<wicri:regionArea>Zoonosis Science Center, Department of Medical Biochemistry and Microbiology, Uppsala University, Uppsala</wicri:regionArea>
</affiliation>
</author>
<author>
<name sortKey="J Rhult, Josef D" sort="J Rhult, Josef D" uniqKey="J Rhult J" first="Josef D" last="J Rhult">Josef D. J Rhult</name>
<affiliation wicri:level="1">
<nlm:affiliation>Section for Infectious Diseases, Department of Medical Sciences, Uppsala University, Uppsala, Sweden.</nlm:affiliation>
<country xml:lang="fr">Suède</country>
<wicri:regionArea>Section for Infectious Diseases, Department of Medical Sciences, Uppsala University, Uppsala</wicri:regionArea>
</affiliation>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">PubMed</idno>
<date when="2017">2017</date>
<idno type="RBID">pubmed:29139346</idno>
<idno type="pmid">29139346</idno>
<idno type="doi">10.1099/jgv.0.000977</idno>
<idno type="wicri:Area/PubMed/Corpus">000356</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000356</idno>
<idno type="wicri:Area/PubMed/Curation">000356</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000356</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en">
<i>In vivo</i>
mallard experiments indicate that zanamivir has less potential for environmental influenza A virus resistance development than oseltamivir.</title>
<author>
<name sortKey="Nykvist, Marie" sort="Nykvist, Marie" uniqKey="Nykvist M" first="Marie" last="Nykvist">Marie Nykvist</name>
<affiliation wicri:level="1">
<nlm:affiliation>Zoonosis Science Center, Department of Medical Biochemistry and Microbiology, Uppsala University, Uppsala, Sweden.</nlm:affiliation>
<country xml:lang="fr">Suède</country>
<wicri:regionArea>Zoonosis Science Center, Department of Medical Biochemistry and Microbiology, Uppsala University, Uppsala</wicri:regionArea>
</affiliation>
</author>
<author>
<name sortKey="Gillman, Anna" sort="Gillman, Anna" uniqKey="Gillman A" first="Anna" last="Gillman">Anna Gillman</name>
<affiliation wicri:level="1">
<nlm:affiliation>Section for Infectious Diseases, Department of Medical Sciences, Uppsala University, Uppsala, Sweden.</nlm:affiliation>
<country xml:lang="fr">Suède</country>
<wicri:regionArea>Section for Infectious Diseases, Department of Medical Sciences, Uppsala University, Uppsala</wicri:regionArea>
</affiliation>
</author>
<author>
<name sortKey="Soderstrom Lindstrom, Hanna" sort="Soderstrom Lindstrom, Hanna" uniqKey="Soderstrom Lindstrom H" first="Hanna" last="Söderström Lindström">Hanna Söderström Lindström</name>
<affiliation wicri:level="1">
<nlm:affiliation>Department of Chemistry, Umeå University, Umeå, Sweden.</nlm:affiliation>
<country xml:lang="fr">Suède</country>
<wicri:regionArea>Department of Chemistry, Umeå University, Umeå</wicri:regionArea>
</affiliation>
</author>
<author>
<name sortKey="Tang, Chaojun" sort="Tang, Chaojun" uniqKey="Tang C" first="Chaojun" last="Tang">Chaojun Tang</name>
<affiliation wicri:level="1">
<nlm:affiliation>Department of Chemistry, Umeå University, Umeå, Sweden.</nlm:affiliation>
<country xml:lang="fr">Suède</country>
<wicri:regionArea>Department of Chemistry, Umeå University, Umeå</wicri:regionArea>
</affiliation>
</author>
<author>
<name sortKey="Fedorova, Ganna" sort="Fedorova, Ganna" uniqKey="Fedorova G" first="Ganna" last="Fedorova">Ganna Fedorova</name>
<affiliation wicri:level="1">
<nlm:affiliation>University of South Bohemia in Ceske Budejovice, Faculty of Fisheries and Protection of Waters, South Bohemian Research Center of Aquaculture and Biodiversity of Hydrocenoses, Vodnany, Czech Republic.</nlm:affiliation>
<country xml:lang="fr">République tchèque</country>
<wicri:regionArea>University of South Bohemia in Ceske Budejovice, Faculty of Fisheries and Protection of Waters, South Bohemian Research Center of Aquaculture and Biodiversity of Hydrocenoses, Vodnany</wicri:regionArea>
</affiliation>
</author>
<author>
<name sortKey="Lundkvist, Ke" sort="Lundkvist, Ke" uniqKey="Lundkvist " first=" Ke" last="Lundkvist"> Ke Lundkvist</name>
<affiliation wicri:level="1">
<nlm:affiliation>Zoonosis Science Center, Department of Medical Biochemistry and Microbiology, Uppsala University, Uppsala, Sweden.</nlm:affiliation>
<country xml:lang="fr">Suède</country>
<wicri:regionArea>Zoonosis Science Center, Department of Medical Biochemistry and Microbiology, Uppsala University, Uppsala</wicri:regionArea>
</affiliation>
</author>
<author>
<name sortKey="Latorre Margalef, Neus" sort="Latorre Margalef, Neus" uniqKey="Latorre Margalef N" first="Neus" last="Latorre-Margalef">Neus Latorre-Margalef</name>
<affiliation wicri:level="1">
<nlm:affiliation>Centre for Ecology and Evolution in Microbial Model Systems (EEMiS), Faculty of Health and Life Sciences, Linnaeus University, Kalmar, Sweden.</nlm:affiliation>
<country xml:lang="fr">Suède</country>
<wicri:regionArea>Centre for Ecology and Evolution in Microbial Model Systems (EEMiS), Faculty of Health and Life Sciences, Linnaeus University, Kalmar</wicri:regionArea>
</affiliation>
</author>
<author>
<name sortKey="Wille, Michelle" sort="Wille, Michelle" uniqKey="Wille M" first="Michelle" last="Wille">Michelle Wille</name>
<affiliation wicri:level="1">
<nlm:affiliation>Zoonosis Science Center, Department of Medical Biochemistry and Microbiology, Uppsala University, Uppsala, Sweden.</nlm:affiliation>
<country xml:lang="fr">Suède</country>
<wicri:regionArea>Zoonosis Science Center, Department of Medical Biochemistry and Microbiology, Uppsala University, Uppsala</wicri:regionArea>
</affiliation>
</author>
<author>
<name sortKey="J Rhult, Josef D" sort="J Rhult, Josef D" uniqKey="J Rhult J" first="Josef D" last="J Rhult">Josef D. J Rhult</name>
<affiliation wicri:level="1">
<nlm:affiliation>Section for Infectious Diseases, Department of Medical Sciences, Uppsala University, Uppsala, Sweden.</nlm:affiliation>
<country xml:lang="fr">Suède</country>
<wicri:regionArea>Section for Infectious Diseases, Department of Medical Sciences, Uppsala University, Uppsala</wicri:regionArea>
</affiliation>
</author>
</analytic>
<series>
<title level="j">The Journal of general virology</title>
<idno type="eISSN">1465-2099</idno>
<imprint>
<date when="2017" type="published">2017</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc>
<textClass></textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">Neuraminidase inhibitors are a cornerstone of influenza pandemic preparedness before vaccines can be mass-produced and thus a neuraminidase inhibitor-resistant pandemic is a serious threat to public health. Earlier work has demonstrated the potential for development and persistence of oseltamivir resistance in influenza A viruses exposed to environmentally relevant water concentrations of the drug when infecting mallards, the natural influenza reservoir that serves as the genetic base for human pandemics. As zanamivir is the major second-line neuraminidase inhibitor treatment, this study aimed to assess the potential for development and persistence of zanamivir resistance in an
<i>in vivo</i>
mallard model; especially important as zanamivir will probably be increasingly used. Our results indicate less potential for development and persistence of resistance due to zanamivir than oseltamivir in an environmental setting. This conclusion is based on: (1) the lower increase in zanamivir IC
<sub>50</sub>
conferred by the mutations caused by zanamivir exposure (2-17-fold); (2) the higher zanamivir water concentration needed to induce resistance (at least 10 µg l
<sup>-1</sup>
); (3) the lack of zanamivir resistance persistence without drug pressure; and (4) the multiple resistance-related substitutions seen during zanamivir exposure (V116A, A138V, R152K, T157I and D199G) suggesting lack of one straight-forward evolutionary path to resistance. Our study also adds further evidence regarding the stability of the oseltamivir-induced substitution H275Y without drug pressure, and demonstrates the ability of a H275Y-carrying virus to acquire secondary mutations, further boosting oseltamivir resistance when exposed to zanamivir. Similar studies using influenza A viruses of the N2-phylogenetic group of neuraminidases are recommended.</div>
</front>
</TEI>
<pubmed>
<MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
<PMID Version="1">29139346</PMID>
<DateRevised>
<Year>2020</Year>
<Month>01</Month>
<Day>08</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1465-2099</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>98</Volume>
<Issue>12</Issue>
<PubDate>
<Year>2017</Year>
<Month>Dec</Month>
</PubDate>
</JournalIssue>
<Title>The Journal of general virology</Title>
<ISOAbbreviation>J. Gen. Virol.</ISOAbbreviation>
</Journal>
<ArticleTitle>
<i>In vivo</i>
mallard experiments indicate that zanamivir has less potential for environmental influenza A virus resistance development than oseltamivir.</ArticleTitle>
<Pagination>
<MedlinePgn>2937-2949</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1099/jgv.0.000977</ELocationID>
<Abstract>
<AbstractText>Neuraminidase inhibitors are a cornerstone of influenza pandemic preparedness before vaccines can be mass-produced and thus a neuraminidase inhibitor-resistant pandemic is a serious threat to public health. Earlier work has demonstrated the potential for development and persistence of oseltamivir resistance in influenza A viruses exposed to environmentally relevant water concentrations of the drug when infecting mallards, the natural influenza reservoir that serves as the genetic base for human pandemics. As zanamivir is the major second-line neuraminidase inhibitor treatment, this study aimed to assess the potential for development and persistence of zanamivir resistance in an
<i>in vivo</i>
mallard model; especially important as zanamivir will probably be increasingly used. Our results indicate less potential for development and persistence of resistance due to zanamivir than oseltamivir in an environmental setting. This conclusion is based on: (1) the lower increase in zanamivir IC
<sub>50</sub>
conferred by the mutations caused by zanamivir exposure (2-17-fold); (2) the higher zanamivir water concentration needed to induce resistance (at least 10 µg l
<sup>-1</sup>
); (3) the lack of zanamivir resistance persistence without drug pressure; and (4) the multiple resistance-related substitutions seen during zanamivir exposure (V116A, A138V, R152K, T157I and D199G) suggesting lack of one straight-forward evolutionary path to resistance. Our study also adds further evidence regarding the stability of the oseltamivir-induced substitution H275Y without drug pressure, and demonstrates the ability of a H275Y-carrying virus to acquire secondary mutations, further boosting oseltamivir resistance when exposed to zanamivir. Similar studies using influenza A viruses of the N2-phylogenetic group of neuraminidases are recommended.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Nykvist</LastName>
<ForeName>Marie</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Zoonosis Science Center, Department of Medical Biochemistry and Microbiology, Uppsala University, Uppsala, Sweden.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Gillman</LastName>
<ForeName>Anna</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>Section for Infectious Diseases, Department of Medical Sciences, Uppsala University, Uppsala, Sweden.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Söderström Lindström</LastName>
<ForeName>Hanna</ForeName>
<Initials>H</Initials>
<AffiliationInfo>
<Affiliation>Department of Chemistry, Umeå University, Umeå, Sweden.</Affiliation>
</AffiliationInfo>
<AffiliationInfo>
<Affiliation>Department of Public Health and Clinical Medicine, Occupational and Environmental Medicine, Umeå University, Umeå, Sweden.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Tang</LastName>
<ForeName>Chaojun</ForeName>
<Initials>C</Initials>
<AffiliationInfo>
<Affiliation>Department of Chemistry, Umeå University, Umeå, Sweden.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Fedorova</LastName>
<ForeName>Ganna</ForeName>
<Initials>G</Initials>
<AffiliationInfo>
<Affiliation>University of South Bohemia in Ceske Budejovice, Faculty of Fisheries and Protection of Waters, South Bohemian Research Center of Aquaculture and Biodiversity of Hydrocenoses, Vodnany, Czech Republic.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Lundkvist</LastName>
<ForeName>Åke</ForeName>
<Initials>Å</Initials>
<AffiliationInfo>
<Affiliation>Zoonosis Science Center, Department of Medical Biochemistry and Microbiology, Uppsala University, Uppsala, Sweden.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Latorre-Margalef</LastName>
<ForeName>Neus</ForeName>
<Initials>N</Initials>
<AffiliationInfo>
<Affiliation>Centre for Ecology and Evolution in Microbial Model Systems (EEMiS), Faculty of Health and Life Sciences, Linnaeus University, Kalmar, Sweden.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Wille</LastName>
<ForeName>Michelle</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Zoonosis Science Center, Department of Medical Biochemistry and Microbiology, Uppsala University, Uppsala, Sweden.</Affiliation>
</AffiliationInfo>
<AffiliationInfo>
<Affiliation>Present address: WHO Collaborating Centre for Reference and Research on Influenza, The Peter Doherty Institute for Infection and Immunity, Melbourne, Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Järhult</LastName>
<ForeName>Josef D</ForeName>
<Initials>JD</Initials>
<AffiliationInfo>
<Affiliation>Section for Infectious Diseases, Department of Medical Sciences, Uppsala University, Uppsala, Sweden.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>J Gen Virol</MedlineTA>
<NlmUniqueID>0077340</NlmUniqueID>
<ISSNLinking>0022-1317</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Relenza</Keyword>
<Keyword MajorTopicYN="N">antiviral resistance</Keyword>
<Keyword MajorTopicYN="N">avian influenza</Keyword>
<Keyword MajorTopicYN="N">drug residues</Keyword>
<Keyword MajorTopicYN="N">neuraminidase inhibitor</Keyword>
<Keyword MajorTopicYN="N">pandemic preparedness</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData>
<History>
<PubMedPubDate PubStatus="pubmed">
<Year>2017</Year>
<Month>11</Month>
<Day>16</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline">
<Year>2017</Year>
<Month>11</Month>
<Day>16</Day>
<Hour>6</Hour>
<Minute>1</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez">
<Year>2017</Year>
<Month>11</Month>
<Day>16</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
<ArticleId IdType="pubmed">29139346</ArticleId>
<ArticleId IdType="doi">10.1099/jgv.0.000977</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/PandemieGrippaleV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000356 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 000356 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    PandemieGrippaleV1
   |flux=    PubMed
   |étape=   Curation
   |type=    RBID
   |clé=     pubmed:29139346
   |texte=   In vivo mallard experiments indicate that zanamivir has less potential for environmental influenza A virus resistance development than oseltamivir.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i   -Sk "pubmed:29139346" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd   \
       | NlmPubMed2Wicri -a PandemieGrippaleV1 

Wicri

This area was generated with Dilib version V0.6.34.
Data generation: Wed Jun 10 11:04:28 2020. Site generation: Sun Mar 28 09:10:28 2021